Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.86 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.64 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.64 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.64 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.64 |
| ▸ | KIF11 | P52732 | 10/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179 | 0.93 | MGLL (1.00) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL28950359 | 0.85 | MGLL (0.63) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| Alcohol SCHEMBL29154486 | 0.83 | MGLL (0.79) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL25413876 | 0.83 | MGLL (0.79) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL213337 | 0.81 | CA2 (0.58) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL14165310 | 0.81 | MGLL (0.76) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29952487 | 0.81 | MGLL (0.65) | MGLLKIF11CA1CA2 | |
| SCHEMBL13667445 | 0.80 | CA2 (0.78) | MGLLCA1CA2 | |
| SCHEMBL197238 | 0.80 | KIF11 (0.78) | TRPV6ORAI1ORAI2ORAI3KIF11 | |
| SCHEMBL13410633 | 0.80 | KIF11 (0.78) | TRPV6ORAI1ORAI2ORAI3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611947-A | Chiral phosphoric acid catalyst and synthesis method thereof | 上海泰坦科技股份有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-115611947-B | Chiral phosphoric acid catalyst and synthesis method thereof | 上海泰坦科技股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-115611947-A | Chiral phosphoric acid catalyst and synthesis method thereof | 上海泰坦科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-112538056-B | Electron transport material and organic electroluminescent device containing same | 南京高光半导体材料有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-112538056-A | Electron transport material and organic electroluminescent device containing same | 南京高光半导体材料有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| EP-3230276-A1 | GLP-1 RECEPTOR MODULATORS | Celgene International II Sarl (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MGLL 1183/4885TRPV6 902/4885ORAI1 1169/4885 |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | MGLL 2688/4885TRPV6 3432/4885ORAI1 4391/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MGLL 1183/4885TRPV6 902/4885ORAI1 1169/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | MGLL 979/4885TRPV6 899/4885ORAI1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.